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Case of Pneumocystis Pneumonia 6 years post-renal transplant while
on Everolimus
Nikita Desai and Ayooluwa Ayoola, (Wayne State University School of Medicine)
Henry Ford Health System, Detroit, Michigan
Learning Objectives
● Presentation of Pneumocystis jirovecii pneumonia >1 year posttransplant
● Role of immunosuppression and prophylaxis in post-transplant
patient

Introduction
● Pneumocystis jirovecii pneumonia (PCP) is a rare cause of pulmonary
infection that primarily affects the immunosuppressed (1).
● Populations at risk include: HIV patients with low CD4 counts,
hematopoietic stem cell and solid organ transplant patients, cancer
patients, and patients with long-term glucocorticoid or
immunomodulator use
● Continued debate on best duration for prophylactic therapy. Currently
is center dependent and tends to range between 6-12 months (2).
● Prophylactic regimen: First line is trimethoprim/sulfamethoxazole
(TMP/SMX), for those with sulfa allergy use atovaquone

Case Description
● Our patient: Ms. P is a 73 year old female who presented to the
Emergency Department with 2 weeks of SOB and generalized
weakness
● She received an iron transfusion 2 days prior to presentation for
newly discovered iron deficiency anemia but had no symptomatic
relief.

● Patient’s current immunosuppresion regimen: tacrolimus 1 mg q12,
prednisone 5mg qDay, and newly substituted everolimus 0.75 mg
q12 for mycophenolate mofetil. Change occurred due to recent skin
cancer diagnosis.
● Concern for everolimus drug-induced pneumonitis versus infectious
process led to holding everolimus and starting infectious work up
● Viral respiratory panel from nasal swab came back negative, sputum
sample for Pneumocystis jirovecii negative, CMV DNA not detected.
Proceeded with Bronchoalveolar Lavage a week later as patient
continued to experience hypoxia requiring oxygen.
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● Repeat CT showed ground-glass opacities with some nodularity.
● Prior to discharge: continued hypoxia requiring 4L NC. Left on
prednisone taper and off of everolimus with follow up scheduled at
Infectious Disease (ID) Clinic and Transplant Clinic.
● At ID clinic, Ms. P’s lab results were all in and led to the final
diagnosis of Pneumocystis jirovecii. She was started on TMP/SMX
q8 PO for 3 weeks
● At 3 week follow up appointment to ID clinic, patient reported
symptomatic improvement with normal oxygen saturations on room
air. She was instructed to continue TMP/SMX three times per week
for 3 months as prophylaxis against PCP.
● Immunosuppresion regimen set by Transplant to tacrolimus 0.5
mg qDay and prednisone 5 mg qDay.

Images
● Past Medical History: Significant for Chronic Kidney Disease. First
kidney transplant in 1996 was from sister. Due to signs of rejection,
she received second kidney in 2012 from daughter. Also, she has a
left lateral neck lesion newly discovered to be squamous cell
carcinoma.

Bronchoalveolar Lavage for PCP

DETECTED (!)

Respiratory Culture

No growth x 2 days

Conclusion
● Typical radiographic findings for PCP are diffuse bilateral,
interstitial infiltrates. When x-ray plain film shows no
abnormalities, CT may show ground glass opacities or cystic lesions.
Findings for everolimus pneumonitis are similar with ground glass
opacities, focal consolidations, nodular opacities, reticulation (1).
● Both PCP and everolimus drug-induced pneumonitis tend to present
with nonspecific symptoms: dyspnea, dry cough, fever, fatigue,
hypoxia, and hemoptysis (3)
● Patients not treated with prophylaxis are most vulnerable during
the first 6 months after transplant (4). With the incorporation of
PCP prophylaxis, incidence of PCP within the first year is quite rare.
Greater immunosuppression increases risk of infection.
● Clinical suspicion of PCP is based on symptoms and radiographic
changes. It is then confirmed with a positive PCP PCR assay. Of
note, co-infection with CMV may increase risk of PCP infection (2).

● ED course:
○ IV fluids
○ CXR: no acute process
○ CT chest: no PE, but evidence of emphysematous change
● She continued to require oxygen and was admitted to the general
medical unit
● On arrival to the floor she was tachypneic and had significant
wheezing. She was started on bronchodilators, glucocorticoids, and
empiric antibiotics.
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● Although rare, this case demonstrates PCP can occur >1 year posttransplant.
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Figure 2. Ms. P’s CT prior to discharge
which shows a node in right upper lobe
as well as scattered ground glass and
nodular opacities
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